41 results about "Enhancing Antibodies" patented technology

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as "RE mutations") per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody¬ dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

Antibodies with novel Fc modification combinations that increase antibody function are described. The novel Fc modification combinations include M252Y / S254T / T256E (YTE) in combination with M428L / N434S (LS) (YTE+LS), YTE+LS in combination with S239D / A330L / I332E (OLE) (YTE+LS+DLE), YTE+LS in combination with G236A / A330L / I332E (YTE+LS+ALE), YTE+LS in combination with G236A / S239D / A330L (DAL) (YTE+LS+DAL) and YTE+LS in combination with G236A / S239D / A330L / I332E (DALE) (YTE+LS+DALE). Glycosylation modifications are optionally included with these combinations.

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.

The present invention discloses a method for enhancing antibody immobilization in an avian reovirus detection sensor. The present invention provides a preparation method for an electrochemical immunosensor for detecting reovirus, comprising the following steps: (1) treating the electrode; (2) modifying the electrode with a nanocomposite; (3) pre-treating before antibody immobilization; (4) antibody immobilization; (5) working electrode and detection. The nanocomposite is a gold-platinum nanocomposite, and the pre-treatment is incubation with a cysteamine hydrochloride solution. It is experimentally proven that the detection linear range of the sensor of the present invention is from 0 to 10 5.82 EID 50 / mL, and the lowest detection limit is 10 0.46 EID 50 / mL. Compared with the method of directly immobilizing antibodies, the detection linear range is increased by 10 times, and it has high sensitivity and good specificity.

The present invention relates to improved antibodies targeting CD163. In particular, the present invention relates to improved antibodies targeting CD163 with improved capabilities in relation to inducing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The invention discloses a halogen modified hapten for enhancing antibody titer and affinity as well as a preparation method and application of the halogen modified hapten, and belongs to the technical field of biochemical engineering. According to the method, an amantadine structure is innovatively and chemically modified, various halogens such as fluorine, chlorine and bromine are introduced, the AMA halogen modified hapten shown in the formula (I) is formed, and the traditional'most similar 'design principle is broken through. Compared with an unmodified hapten, the hapten modified by halogen in the invention has the advantages that the titer of the polyclonal antibody on amantadine can be obviously improved by 3.4-14 times; wherein the haptens A5 and A6 can obviously improve the titer of the monoclonal antibody to amantadine by 3-18 times, and the affinity is improved by 10.8-16.1 times. The invention provides a new thought and a new method for the rational design of the hapten of the small molecule compound and the preparation of the high-affinity antibody, and the related halogen modification type and quantity strategy can also provide valuable reference for the design of the hapten of other small molecule compounds.

The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Disclosed herein are cells (e.g, immune cells such as T cells) engineered to contain and / or express a Lysis Sensor Receptors (LSR) comprising an extracellular domain with affinity and specificity for an intracellular product of a diseased cell such as a cancer cell; a transmembrane element and at least one signaling element, and a chimeric antigen receptor (CAR) comprising an extracellular domain with affinity and specificity for an extracellular product of a diseased cell such as a cancer cell; a transmembrane element and at least one signaling element. Also provided herein are various uses of such engineered cells, including in the treatment of cancer, for example to enhance T cell activity (e.g, TIL and / or CAR-T cell activity) and / or to enhance antibody-based therapy, such as cancer immunotherapy.

The present invention relates to the identification of key residues within mouse IgG3 antibodies (mAbs) that are responsible for intermolecular cooperativity and their transfer into IgG1 antibodies in order to enhance their functional affinity and direct a cell killing.

This application relates to general glycoform compositions and methods for enhancing antibody efficacy. The present invention relates to compositions comprising an antibody or a binding fragment thereof, further comprising a general Fc glycoform, and methods of use.

This article describes antibodies or antigen-binding fragments that specifically bind to GPRC5D. Additionally, it includes monovalent antibodies or antigen-binding fragments that specifically bind to GPRC5D. The Fc regions of these antibodies contain K248E and T437R mutations (referred to as “RE mutations”) according to the EU numbering system. The described antibodies, when expressed in host cells lacking fucosylation capacity, exhibit enhanced antibody-dependent cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The invention provides a preparation method of an antibody conjugate containing an sLeX tetrasaccharide structure, which comprises the following steps: S1, sequentially adding Endo S2 enzyme and alpha-L-fucosidase into a target antibody, and respectively analyzing glycosylation to avoid modification site conflict or carbohydrate chain structure interference; s2, adding the accurately represented antibody in the S1, B4GalT1 and UDP-Gal into a Tris-HCl system containing Mn < 2 + >, and incubating to obtain a reaction solution I; s3, the reaction liquid I, ST3Gal3, CMP-Neu5Ac and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is carried out; adding CMP-N-acyl neuraminic acid phosphodiesterase for reaction, and purifying Protein A to obtain a purified antibody I; s4, the purified antibody I, alpha1, 3 FucT-2HR, GDP-Fuc and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is performed; and purifying Protein A to obtain a target product. According to the modified antibody obtained by the invention, while the targeting property is improved, the binding affinity of the antibody and a tumor cell surface antigen can be enhanced, so that the immune blocking activity of the antibody is further enhanced, and dual improvement of the targeting property and the activity is realized.

The invention belongs to the technical field of biological medicine, and particularly relates to a macrophage bionic vesicle nano preparation as well as a preparation method and application thereof. The invention provides a macrophage bionic vesicle nano preparation, which is characterized in that a tumor targeting peptide is used for modifying a macrophage bionic vesicle, and a targeting NSUN family methyltransferase siRNA (small interfering Ribonucleic Acid) is wrapped. The macrophage bionic vesicles modified by the tumor targeting peptide have good gastric cancer cell targeting property, the NSUN expression level of gastric cancer cells can be inhibited by wrapping targeted NSUN family methyltransferase siRNA, the abnormal modification level of gastric cancer m5C is reduced, and the effect of enhancing the treatment of the gastric cancer by the PD-1 antibody is achieved. The results of the embodiment show that the macrophage bionic vesicle nano preparation provided by the invention acts on gastric cancer cells, and can specifically target the gastric cancer cells, induce ferroptosis of the gastric cancer cells, improve the curative effect of a PD-1 antibody, prolong the survival time of mice and improve the tumor immune microenvironment.

The present invention provides a covalent conjugate. The conjugate includes an antibody or antibody derivative, at least two LL37-derived polypeptides, and a payload. The antibody or antibody derivative targets a cell that has phosphatidylserine in its outer leaflet. The payload includes: a small molecule cytotoxic drug of less than 3 kDa, or a plurality thereof; or a peptide or protein of less than 100 kDa. Uses and methods of using these covalent conjugates are also provided, related to enhancing delivery of the antibody / derivative or the payload, e.g. to enhance therapeutic or diagnostic effectiveness.

This invention relates to improving cancer treatment methods using PD-1 / PD-L1 antibodies. In particular, this invention is based on the finding that patients with a TGFβ-specific T cell response are likely to show favorable outcomes in cancer treatment with PD-1 / PD-L1 antibodies. Therefore, this invention provides treatment for such patient groups with PD-1 / PD-L1 antibodies and actively promotes the TGFβ-specific T cell response in order to enhance the therapeutic effect of PD-1 / PD-L1 antibodies.

The present application relates to the technical field of bio-chemical engineering, and particularly relates to a halogen-modified hapten for enhancing antibody affinity, and a preparation method and application thereof. The present application provides a halogen-modified sulfonamide hapten for enhancing antibody affinity, which is obtained by adopting halogen-modified sulfonamides, and the antibody prepared by the halogen-modified sulfonamide hapten has relatively high titer and affinity. The present application provides a new and effective approach for preparing high-affinity sulfonamide antibodies.

Provided herein are methods and compositions for purifying antibodies. Purification is achieved by increasing the binding capacity of protein A chromatography by covalent attachment of a protein A domain (E, D, A, B, C), or domain Z, or a functional variant thereof, to Drosophila melanogaster transcription factor Ultrabithorax (Ubx) materials. The compositions include fusion proteins containing Drosophila melanogaster transcription factor Ultrabithorax (Ubx) or a fragment thereof and an immunoglobulin binding protein. In some embodiments, the immunoglobulin binding protein is a protein A domain, a protein Z domain or a fragment thereof.

The present invention relates to a novel immune-enhancing protein capable of enhancing antibody-forming ability, and use thereof. The vaccine composition comprising an antigen and a gPA-1-derived protein of Pneumocystis carinii or a gpl20-derived protein of human immunodeficiency virus (HIV), of the present invention, has an antibody-forming ability against a disease antigen that is superior to that of other vaccines, and thus a more effective vaccine can be prepared.

The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

The invention relates to a CD70-targeting antibody or a CD70-binding antigen binding fragment, and a preparation method and application of the CD70-targeting antibody or the CD70-binding antigen binding fragment. The antibody targeting CD70 or the antigen binding fragment binding CD70 can block CD70 / CD27 signals in a targeted manner, and kill cancer cells expressing CD70 by enhancing antibody-dependent cell-mediated cytotoxic effect, antibody-dependent cell-mediated phagocytosis and complement-dependent cytotoxic effect, so that immune monitoring on solid tumors is recovered.

Provided herein are methods and compositions for purifying antibodies. Purification is achieved by increasing the binding capacity of protein A chromatography by covalent attachment of a protein A domain (E, D, A, B, C), or domain Z, or a functional variant thereof, to Drosophila melanogaster transcription factor Ultrabithorax (Ubx) materials. The compositions include fusion proteins containing Drosophila melanogaster transcription factor Ultrabithorax (Ubx) or a fragment thereof and an immunoglobulin binding protein. In some embodiments, the immunoglobulin binding protein is a protein A domain, a protein Z domain or a fragment thereof.

The application discloses a method for modifying pH sensitivity of an antibody based on yeast display. A degenerate codon VAM (coding H, E, D, K, N, Q) is used to construct a yeast display library for at least two region combinations in LCDR1, HCDR1 and HCDR3, and 1-2 mutations are introduced into each CDR region, taking the antibody to be modified as a template. The library is transformed into Saccharomyces cerevisiae EBY100 to induce expression, and fast dissociation clones are enriched through four rounds of flow sorting (including pH 7.4 binding, pH 6.0 non-binding and'saturated binding-acid dissociation-neutral re-binding' screening). The obtained antibody has a KD ratio at pH 5.8 to pH 7.4 of up to 674.46, an expression amount of up to 263.3 mg / L, excellent physicochemical properties, and can enhance the curative effect of antibody conjugated drugs and improve the therapeutic index.

Antibodies having enhanced biodistribution and / or pharmacokinetics obtained through disruption of one or more clusters of surface-exposed positively charged amino acids are provided. Also provided are methods of enhancing the biodistribution and / or pharmacokinetics of an antibody. The enhanced antibodies find use in immunotherapy, radiotherapy, and in vivo imaging.

The present disclosure relates to improved antibodies targeting CD163. In particular, the present disclosure relates to improved antibodies targeting CD163 with improved capabilities in relation to inducing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).

The present invention addresses the problem of providing, as an antibody titer-improving agent (e.g., an adjuvant) that continues the effect of vaccination by vaccines or the like, a safe, simple and economical antibody titer-improving agent (e.g., an adjuvant) that can be easily ingested by all ages, and a method for producing the same. The present invention relates to a method for increasing antibody titer and a method for enhancing the effect of a vaccine using Lactobacillus bulgaricus OLL1073R-1 or a culture thereof, and an antibody titer increasing agent, such as an adjuvant, comprising Lactobacillus bulgaricus OLL1073R-1 or a culture thereof.

This invention belongs to the field of biology and discloses a VHH antibody against human FcRn and its applications. The complementarity-determining regions (CDR1-CDR3) of the VHH antibody are shown in SEQ ID NO. 1-9. Some examples of the anti-human FcRn VHH antibodies of this invention can specifically bind to human FcRn; they can replace traditional antibodies and be used in the treatment and diagnosis of autoimmune diseases; the fused Fc fragment targets and binds to the FcRn receptor, effectively reducing the half-life of IgG in the blood while enhancing antibody targeting. Some examples of the anti-human FcRn VHH antibodies of this invention, by fusing the Fc fragment, can increase their affinity for the FcRn receptor, effectively reducing the half-life of IgG in autoimmune diseases, while also mitigating ADCC and CDC effects.

The invention belongs to the field of biological treatment, and particularly relates to application of an adenosine A2AR (adenosine A2A receptor) antagonist in preparation of a medicine for enhancing PD-1 antibody immunotherapy. The invention specifically relates to application of the adenosine A2AR antagonist combined with a PD-1 antibody and / or a PD-L1 antibody in treatment of tumors including esophageal squamous cell carcinoma, gastric cancer, colorectal cancer, renal cell carcinoma, melanin and other tumors in enhancement of immunotherapy effects. According to the adenosine A2AR antagonist and PD-1 antibody and / or PD-L1 antibody combined medication scheme, tumor immunotherapy can be conducted on digestive tract tumors and other tumors through the PD-1 antibody and / or PD-L1 antibody, and compared with PD-1 antibody or PD-L1 antibody single-drug treatment and immunity activation, tumor growth can be remarkably inhibited, and the tumor treatment effect can be improved. The method has a wide application prospect.

The invention relates to a novel artificial enhancement subelement, an assembly and a construction method and application of the novel artificial enhancement subelement. The invention provides an artificial enhancer element capable of guiding high-level expression of a target gene as well as an assembly and application of the artificial enhancer element. Preferably, the artificial enhancer element and the assembly of the artificial enhancer element can guide the high expression level of an antibody gene and enhance the diversity of an antibody. The designed and assembled artificial enhancer element and assembly have the function of a super enhancer, can construct a targeting vector, guide high-level expression of a target gene, especially an antibody gene, and increase diversity of antibody gene expression products. Expression of luciferase in mouse myeloma cells is guided according to the artificial enhancer element and the composition thereof, but the artificial enhancer element and the composition thereof can be generally used for expression of target genes in mice, preferably expression of antibody genes.